Similar considerations apply to further immunotherapies, that rely on tumor cell lysis mediated by other cytotoxic lymphocytes, especially the inhibition of checkpoints for T cell activation e.g., by anti-CTLA4, anti-PD1 or anti-PDL1 antibodies, as well as therapies with engineered T cells. The gene discussed is CD274; the disease is neoplasm.